-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Generation Bio (NASDAQ:GBIO) and Citius Pharmaceuticals (NASDAQ:CTXR) Head to Head Review
Generation Bio (NASDAQ:GBIO) and Citius Pharmaceuticals (NASDAQ:CTXR) Head to Head Review
Generation Bio (NASDAQ:GBIO – Get Rating) and Citius Pharmaceuticals (NASDAQ:CTXR – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.
Profitability
This table compares Generation Bio and Citius Pharmaceuticals' net margins, return on equity and return on assets.
Get Generation Bio alerts:Net Margins | Return on Equity | Return on Assets | |
Generation Bio | N/A | -39.52% | -31.03% |
Citius Pharmaceuticals | N/A | -24.78% | -22.97% |
Institutional and Insider Ownership
93.9% of Generation Bio shares are held by institutional investors. Comparatively, 25.4% of Citius Pharmaceuticals shares are held by institutional investors. 20.7% of Generation Bio shares are held by insiders. Comparatively, 14.8% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Generation Bio has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500.Analyst Recommendations
This is a summary of recent recommendations and price targets for Generation Bio and Citius Pharmaceuticals, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Generation Bio | 0 | 2 | 5 | 0 | 2.71 |
Citius Pharmaceuticals | 0 | 0 | 2 | 0 | 3.00 |
Generation Bio presently has a consensus price target of $16.75, suggesting a potential upside of 165.03%. Citius Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 367.29%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Generation Bio.
Valuation & Earnings
This table compares Generation Bio and Citius Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Generation Bio | N/A | N/A | -$119.15 million | ($2.34) | -2.70 |
Citius Pharmaceuticals | N/A | N/A | -$23.05 million | ($0.20) | -5.35 |
Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.
Summary
Citius Pharmaceuticals beats Generation Bio on 6 of the 11 factors compared between the two stocks.
About Generation Bio
(Get Rating)
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
About Citius Pharmaceuticals
(Get Rating)
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.
Generation Bio (NASDAQ:GBIO – Get Rating) and Citius Pharmaceuticals (NASDAQ:CTXR – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.
世代生物(納斯達克:GBIO-GET評級)和花旗製藥(納斯達克:CTXR-GET評級)都是小盤醫療公司,但哪一家是優勢業務?我們將根據這兩家公司的機構所有權、盈利能力、股息、估值、分析師建議、風險和收益等方面的實力進行比較。
Profitability
盈利能力
This table compares Generation Bio and Citius Pharmaceuticals' net margins, return on equity and return on assets.
此表比較了世代生物和Citius製藥公司的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Generation Bio | N/A | -39.52% | -31.03% |
Citius Pharmaceuticals | N/A | -24.78% | -22.97% |
淨利潤率 | 股本回報率 | 資產回報率 | |
新一代生物 | 不適用 | -39.52% | -31.03% |
花旗集團製藥公司 | 不適用 | -24.78% | -22.97% |
Institutional and Insider Ownership
機構和內部人持股
93.9% of Generation Bio shares are held by institutional investors. Comparatively, 25.4% of Citius Pharmaceuticals shares are held by institutional investors. 20.7% of Generation Bio shares are held by insiders. Comparatively, 14.8% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
世代生物93.9%的股份由機構投資者持有。相比之下,機構投資者持有Citius PharmPharmticals 25.4%的股份。世代生物20.7%的股份由內部人士持有。相比之下,花旗製藥14.8%的股份由內部人士持有。強大的機構持股表明,大型基金管理公司、捐贈基金和對衝基金相信,一隻股票有望實現長期增長。
Risk and Volatility
風險和波動性
Analyst Recommendations
分析師建議
This is a summary of recent recommendations and price targets for Generation Bio and Citius Pharmaceuticals, as reported by MarketBeat.
這是MarketBeat報道的Generation Bio和Citius PharmPharmticals最近的建議和目標價的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Generation Bio | 0 | 2 | 5 | 0 | 2.71 |
Citius Pharmaceuticals | 0 | 0 | 2 | 0 | 3.00 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
新一代生物 | 0 | 2 | 5 | 0 | 2.71 |
花旗集團製藥公司 | 0 | 0 | 2 | 0 | 3.00 |
Generation Bio presently has a consensus price target of $16.75, suggesting a potential upside of 165.03%. Citius Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 367.29%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Generation Bio.
Generation Bio目前的共識目標價為16.75美元,這意味着潛在的上漲165.03%。Citius PharmPharmticals的共識目標價為5美元,暗示潛在上行367.29%。考慮到Citius PharmPharmticals更強的共識評級和更高的可能上行空間,分析師顯然認為Citius PharmPharmticals比Generation Bio更有利。
Valuation & Earnings
估值與收益
This table compares Generation Bio and Citius Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
該表格比較了世代生物和Citius PharmPharmticals的營收、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Generation Bio | N/A | N/A | -$119.15 million | ($2.34) | -2.70 |
Citius Pharmaceuticals | N/A | N/A | -$23.05 million | ($0.20) | -5.35 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
新一代生物 | 不適用 | 不適用 | -1.1915億美元 | ($2.34) | -2.70 |
花旗集團製藥公司 | 不適用 | 不適用 | -2305萬美元 | ($0.20) | -5.35 |
Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.
Citius PharmPharmticals的市盈率低於Generation Bio,這表明它目前是兩隻股票中更負擔得起的一隻。
Summary
摘要
Citius Pharmaceuticals beats Generation Bio on 6 of the 11 factors compared between the two stocks.
花旗製藥在兩隻股票比較的11個因素中有6個擊敗了世代生物。
About Generation Bio
關於世代生物
(Get Rating)
(獲取評級)
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
世代生物公司是一家基因藥物公司,開發治療罕見和流行疾病的療法。該公司提供一系列計劃,包括針對罕見和流行的肝臟和視網膜疾病的計劃。它還側重於骨骼肌、中樞神經系統和腫瘤學的疾病。該公司前身為Torus治療公司,並於2017年11月更名為Generation Bio Co.。世代生物公司成立於2016年,總部設在馬薩諸塞州劍橋市。
About Citius Pharmaceuticals
關於Citius製藥公司
(Get Rating)
(獲取評級)
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Citius PharmPharmticals,Inc.是一家專業製藥公司,致力於危重護理產品的開發和商業化,重點是附屬癌症護理中的抗感染產品、處方藥和間充質幹細胞治療。該公司正在開發五種專利產品,包括Mino-Lok,一種通過挽救感染的導管來治療導管相關血流感染的抗生素鎖定解決方案;Mino-Wrap,一種基於液化凝膠的包裹,用於減少乳房重建手術後的組織擴張器感染;Halo-Lido,一種皮質類固醇-利多卡因局部製劑,旨在為痔瘡患者提供抗炎和麻醉緩解;NoveCite,一種用於治療急性呼吸道疾病綜合徵的間質幹細胞療法;以及I/Ontak,一種用於治療持續性或複發性皮膚T細胞淋巴瘤患者的經過改造的IL-2白喉毒素融合蛋白。Citius製藥公司成立於2007年,總部設在新澤西州克蘭福德。
Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.
接受《世代生物日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對Generation Bio及相關公司評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧